Gebro Pharma AG - نتائج البحث

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

leflunomide medac

medac gesellschaft für klinische spezialpräparate mbh - leflunomide - arthritis, rheumatoid - selective immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard).recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

tovanor breezhaler

novartis europharm limited - glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - tovanor breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited - indacaterol, mometasone furoate - asthma - drugs for obstructive airway diseases, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

zimbus breezhaler

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - asthma - drugs for obstructive airway diseases, - maintenance treatment of asthma in adults whose disease is not adequately controlled.